We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 46% in a year while the S&P 500 rose 11%.
“Net sales increased 12.7% organically, driven by our High Value Product Components business which benefited from continued strength in Biologics”
| The company | Sales growth sped up 4 quarters in a row |
| Latest filing | 8-K, Oct 29 |
Tue Nov 10: Ex-dividend, $0.26 a shareAt the open. Pays Nov 18.
After its last 4 reports it closed +3.6% on average, higher 2 of 4 times.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
WST is #3 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Expected to report Thu Feb 18, before the open (in 107 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $874.5M.
“West Vantage sales decreased 6.6 percent organically in Q326, due to the planned loss of a CGM customer.”
WST gives its mix in its presentation's charts, not in a table we read.
| Measure | Figure |
|---|---|
| Net sales | $3.41B to $3.42B |
Sales grew 7.4% a year over 5 years, fiscal 2020 to 2025.
Pays $1.04 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | +4.2% | +3.2% | open |
| Jul 23, 2026 | +7.4% | -0.8% | -5.8% |
| Apr 23, 2026 | +12.2% | +12.9% | +7.6% |
Sales grew in six of the last seven years, to $3.1B in 2025. It made a profit in each of the eight years.
One insider sold $2.8M across 3 filings in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: WST is 0.1% of VIG, 0.1% of SCHG, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
“With our range of proprietary technologies, we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”
WST scores 17 today, which Breakaway calls Excellent. It is #3 of 85 in Medical Devices by Quality Score, with 6 of 14 chart checks firing. Up 46% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
WST scores 17 today, which Breakaway calls Excellent (15 to 19). That is #3 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind WST's 17.
One insider sold $2.8M across 3 filings in the last 6 months. No open-market buys on record. The newest is Annette F. Favorite, Sr. VP & Chief HR Officer, who sold $960K on Sep 8. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.